Levetiracetam or Phenytoin as Prophylaxis for Status Epilepticus: Secondary Analysis of the "Approaches and Decisions in Acute Pediatric Traumatic Brain Injury Trial" (ADAPT) Dataset, 2014-2017.
Nasim AhmedLarissa RussoYen-Hong KuoPublished in: Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies (2024)
In ADAPT, the decision to use prophylactic levetiracetam versus phenytoin failed to show an association with occurrence of subsequent SE, or mortality. However, we are unable to exclude the possibility that selecting levetiracetam rather than phenytoin for prophylaxis was associated with greater prevalence of SE and mortality. We are unable to make any recommendation about one prophylactic anticonvulsant medication over the other, but recommend that further larger, contemporary studies in severe pediatric TBI are carried out.
Keyphrases
- traumatic brain injury
- risk factors
- cardiovascular events
- liver failure
- drug induced
- risk assessment
- healthcare
- clinical trial
- early onset
- severe traumatic brain injury
- respiratory failure
- coronary artery disease
- cardiovascular disease
- emergency department
- type diabetes
- phase ii
- hepatitis b virus
- intensive care unit
- randomized controlled trial
- young adults
- childhood cancer
- extracorporeal membrane oxygenation
- electronic health record